Last year's ESMO in Paris (Endpoints News)
October 17, 2023 03:53 PM EDTUpdated October 20, 01:53 AM
R&D
Pharma

Up­dat­ed: ES­MO em­bar­go break leads can­cer con­fer­ence to re­lease da­ta for Bris­tol My­ers, J&J, No­var­tis, As­traZeneca

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Reynald Castañeda

Deputy Editor

A bro­ken em­bar­go on the high­est-pro­file ab­stracts at this year’s Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy has forced the con­fer­ence or­ga­niz­er to re­lease da­ta from the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times